PEAK ATP® (Disodium Adenosine Triphosphate)

Evidence Level
Limited
2 Clinical Trials
4 Documented Benefits
2/5 Evidence Score

Peak ATP® (TSI Group) is a patented form of adenosine 5'-triphosphate disodium — the only nutritional ingredient structurally identical to the ATP produced and used by the human body. Unlike supplements that support ATP production indirectly (creatine, CoQ10, D-ribose), peak ATP® provides ATP directly as a signaling molecule that improves blood flow, muscle excitability, and fatigue resistance through extracellular purinergic receptor activation. Industry-funded (TSI Group), largely single-team trials have reported improvements in strength, lean body mass, and muscle thickness at 400 mg/day; the one independent trial (2004) was largely null, so the evidence remains preliminary and awaits independent replication.

Studied Dose 400 mg/day (acute pre-exercise or chronic for 12 weeks).
Active Compound Adenosine 5'-triphosphate disodium (ATP); PEAK ATP® branded form; 400 mg/day dose.

Benefits

Strength and lean body mass gains

A 12-week double-blind RCT in resistance-trained men found peak ATP® (400 mg/day) plus resistance training significantly increased muscle thickness, lean body mass, and total body strength vs placebo plus training. A pooled analysis reported a modest improvement in maximal strength with ATP supplementation, but the literature is dominated by industry-funded, single-team studies and the effect size is small, with limited independent replication.

Fatigue resistance and endurance maintenance

A single manufacturer-funded trial reported that acute peak ATP® (400 mg) helped maintain peak force output during repeated high-intensity sets — reducing fatigue rate and preserving peak torque in later sets of exhaustive exercise. This anti-fatigue mechanism is distinct from energy production support (creatine) and works through improved blood flow and reduced muscle fatigue signaling.

Blood flow and muscle vasodilation

Extracellular ATP activates P2Y purinergic receptors on endothelial cells, triggering nitric oxide and prostaglandin release that drives vasodilation in active muscle. This blood flow enhancement improves oxygen and nutrient delivery to working muscle — complementary to NO-boosting ingredients like L-citrulline but through a completely different mechanism.

Amino acid absorption enhancement

Early research (not cited on this page) suggests oral peak ATP® may enhance amino acid absorption following protein consumption in younger and older adults; this finding is preliminary and not yet independently confirmed. ATP's role in intestinal amino acid transport (stimulating P2Y receptors on enterocytes to enhance amino acid uptake) and is being explored as a way to support amino-acid absorption from protein.

Mechanism of action

1

Extracellular purinergic receptor signaling

Orally consumed ATP is not primarily absorbed intact into circulation — instead, it acts as an extracellular signaling molecule in the gut and vasculature by activating P2X and P2Y purinergic receptors on intestinal epithelium, endothelial cells, and red blood cells. P2Y receptor activation triggers NO-mediated vasodilation, P2X activation enhances muscle calcium release for stronger contractions, and intestinal P2Y signaling enhances amino acid transporter activity. This extracellular signaling mechanism explains ATP's efficacy despite limited systemic absorption.

Clinical trials

1
Peak ATP® for Muscle Mass and Strength — Clinical Trial

Randomized, double-blind, placebo-controlled trial of peak ATP® (400 mg/day disodium ATP) + resistance training vs placebo + training in 21 resistance-trained men for 12 weeks. (Nutr Metab)

21 resistance-trained men. 12-week intervention.

Peak ATP® increased quad muscle thickness (~+1.7 cm), lean body mass (~+1.7 kg), vertical jump power (~+30%), 1RM strength vs placebo. Critical caveat: striking effect sizes for a 12-week RT trial; small sample (n=21); industry-funded (TSI Group). Effect sizes vastly exceed typical resistance training adaptations — warrants independent replication. The mechanism (oral ATP supplementation increasing extracellular ATP without raising intracellular muscle ATP) is biologically debated.

2
ATP Supplementation for Strength — Evidence Synthesis

Evidence review and pooled analysis of 5 human clinical studies (2000-2022) on oral ATP supplementation effects on strength and power performance.

Pooled across 5 ATP studies.

ATP supplementation modestly improved maximal strength vs placebo. Effect size modest. Critical caveat: limited number of independent trials; substantial industry funding across the literature. Generally underwhelming evidence relative to creatine (which has hundreds of trials and Cochrane-level evidence).

Side effects and drug interactions

Common Potential side effects

Well tolerated at 400 mg/day in all clinical studies up to 12 weeks
No significant adverse events reported across all published RCTs
High-purine content — relevant for gout sufferers; consult physician

Important Drug interactions

Antiplatelet/anticoagulant medications — ATP activates platelet P2Y receptors; theoretical additive antiplatelet effect
Dipyridamole — inhibits adenosine metabolism; may potentiate ATP effects; consult physician
No clinically significant pharmacokinetic drug interactions at 400 mg/day

Frequently asked questions about PEAK ATP® (Disodium Adenosine Triphosphate)

What is PEAK ATP?

Peak ATP® (TSI Group) is a patented form of adenosine 5'-triphosphate disodium — the only nutritional ingredient structurally identical to the ATP produced and used by the human body.

What is PEAK ATP used for?

PEAK ATP is researched primarily for Athletic Performance, Muscle & Recovery, and Energy. A 12-week double-blind RCT in resistance-trained men found peak ATP® (400 mg/day) plus resistance training significantly increased muscle thickness, lean body mass, and total body strength vs placebo plus training.

What is the recommended dosage of PEAK ATP?

The clinically studied dose is 400 mg/day (acute pre-exercise or chronic for 12 weeks). Always follow the product label and check with a healthcare provider for personal advice.

Is PEAK ATP safe, and does it have side effects?

For most healthy adults, PEAK ATP is well tolerated at studied doses. Reported effects can include: Well tolerated at 400 mg/day in all clinical studies up to 12 weeks No significant adverse events reported across all published RCTs It may also interact with some medications. PEAK ATP is not right for everyone, so check with a healthcare provider first if you are pregnant or breastfeeding, have a medical condition, or take prescription medication.

Does PEAK ATP interact with any medications?

Possible interactions include: Antiplatelet/anticoagulant medications — ATP activates platelet P2Y receptors; theoretical additive antiplatelet effect Dipyridamole — inhibits adenosine metabolism; may potentiate ATP effects; consult physician If you take prescription medication, check with a pharmacist or doctor before using it.

How strong is the scientific evidence for PEAK ATP?

NutraSmarts rates the evidence for PEAK ATP as Limited (2 out of 5). It is backed by 2 clinical trials and 4 cited references summarized on this page. A higher rating reflects more, larger, and better-designed human studies.

References(4 citations)

Evidence ratings on NutraSmarts are based on the totality of human clinical research, with emphasis on randomized controlled trials, meta-analyses, and systematic reviews. The references below directly support claims made throughout this page.

  1. Wilson JM, Joy JM, Lowery RP, Roberts MD, Lockwood CM, Manninen AH, et al. Effects of oral adenosine-5'-triphosphate supplementation on athletic performance, skeletal muscle hypertrophy and recovery in resistance-trained men. Nutrition & Metabolism. 2013;10(1):57. doi: 10.1186/1743-7075-10-57.PubMedUsed to support: 12-week RCT of oral ATP (peak ATP, 400 mg/day) in resistance-trained men reporting greater gains in strength, power, lean mass, and muscle thickness versus placebo. Headline efficacy reference, but it is industry-funded (TSI/Rathmacher group) and the benefit is via extracellular signaling/blood flow, not raised intramuscular ATP.
  2. Rathmacher JA, Fuller JC Jr, Baier SM, Abumrad NN, Angus HF, Sharp RL Adenosine-5'-triphosphate (ATP) supplementation improves low peak muscle torque and torque fatigue during repeated high intensity exercise sets. Journal of the International Society of Sports Nutrition. 2012;9(1):48. doi: 10.1186/1550-2783-9-48.PubMedUsed to support: RCT showing 400 mg/day oral ATP for 15 days improved low peak torque and reduced torque fatigue during repeated high-intensity sets. Supports the strength/anti-fatigue claim; small sample and manufacturer (Rathmacher/TSI) authorship temper the evidence.
  3. Jordan AN, Jurca R, Abraham EH, Salikhova A, Mann JK, Morss GM, et al. Effects of oral ATP supplementation on anaerobic power and muscular strength. Medicine and Science in Sports and Exercise. 2004;36(6):983-90. doi: 10.1249/01.mss.0000128198.97260.8b.PubMedUsed to support: Earlier independent placebo-controlled trial of enterically coated oral ATP that found no significant change in total blood ATP and largely null effects on anaerobic power/strength. Included for honest balance: it tempers the efficacy claims and underscores that oral ATP is not absorbed intact, with benefits (when seen) attributed to extracellular mechanisms.
  4. Jager R, Roberts MD, Lowery RP, Joy JM, Cruthirds CL, Lockwood CM, et al. Oral adenosine-5'-triphosphate (ATP) administration increases blood flow following exercise in animals and humans. Journal of the International Society of Sports Nutrition. 2014;11:28. doi: 10.1186/1550-2783-11-28.PubMedUsed to support: Mechanistic study showing oral ATP increases post-exercise blood flow in animals and humans, supporting the proposed extracellular/vasodilatory mechanism (rather than raised intramuscular ATP). Important mechanistic backing, but again industry-affiliated (TSI/Rathmacher-Wilson group) and focused on a surrogate (blood flow) rather than performance outcomes.